Log In
Print
BCIQ
Print
Print this Print this
 

Contrave, Mysimba, naltrexone SR/bupropion SR (NB32)

  Manage Alerts
Collapse Summary General Information
Company Orexigen Therapeutics Inc.
DescriptionFixed-dose combination of naltrexone sustained release (SR) and bupropion SR
Molecular Target Mu opioid receptor (MOR) (OPRM1)
Mechanism of ActionMu opioid receptor antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationObesity
Indication DetailsTreat obesity
Regulatory Designation U.S. - Special Protocol Assessment (Treat obesity);
U.S. - Undisclosed Review (Treat obesity);
EU - Standard Review (Treat obesity)
Partner Takeda Pharmaceutical Co. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$1,050.0M

$50.0M

$1,000.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today